アヤワスカ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "アヤワスカ" in Japanese language version.

refsWebsite

Global rank Japanese rank

21nih.gov

4^th place

24^th place

15doi.org

2^nd place

6^th place

3erowid.org

3,887^th place

low place

2nii.ac.jp

304^th place

20^th place

1shitennoji.ac.jp

low place

5,115^th place

1sagami-wu.ac.jp

low place

7,559^th place

1berkeley.edu

580^th place

1,954^th place

1nikkeibp.co.jp

1,415^th place

95^th place

1forbesjapan.com

5,753^rd place

343^rd place

1cpnp.org

low place

1scielo.br

1,606^th place

7,107^th place

1plos.org

2,112^th place

1,782^nd place

1sciencedirect.com

149^th place

558^th place

1kahpi.net

low place

1ouramazingworld.org

low place

berkeley.edu

news.berkeley.edu

Anwar, Yasmin (2019年5月6日). “Ayahuasca fixings found in 1,000-year-old Andean sacred bundle” (英語). Berkeley News. 2019年5月16日閲覧。

cpnp.org

mhc.cpnp.org

Malcolm, Benjamin J.; Lee, Kelly C. (2017). “Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?”. Mental Health Clinician 7 (1): 39–45. doi:10.9740/mhc.2017.01.039.

doi.org

dos Santos, Rafael G.; Bouso, José Carlos; Hallak, Jaime E. C.; et al. (2017). “Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies”. Therapeutic Advances in Psychopharmacology 7 (4): 141–157. doi:10.1177/2045125316689030. PMC 5433617. PMID 28540034.
Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H.; et al. (2016). “Clinical applications of hallucinogens: A review.”. Experimental and Clinical Psychopharmacology 24 (4): 229–268. doi:10.1037/pha0000084. PMC 5001686. PMID 27454674.
Palhano-Fontes F, Barreto D, Onias H, et al. (2019-3). “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial”. Psychol Med 49 (4): 655–663. doi:10.1017/S0033291718001356. PMC 6378413. PMID 29903051.
Riba, J. (2003). “Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics”. Journal of Pharmacology and Experimental Therapeutics 306 (1): 73–83. doi:10.1124/jpet.103.049882. PMID 12660312.
Malcolm, Benjamin J.; Lee, Kelly C. (2017). “Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?”. Mental Health Clinician 7 (1): 39–45. doi:10.9740/mhc.2017.01.039.
Morales-García, Jose A.; de la Fuente Revenga, Mario; Alonso-Gil, Sandra; et al. (2017). “The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro”. Scientific Reports 7 (1): 5309. doi:10.1038/s41598-017-05407-9. PMC 5509699. PMID 28706205.
Osório, Flávia de L.; Sanches, Rafael F.; Macedo, Ligia R.; dos Santos, Rafael G.; Maia-de-Oliveira, João P.; Wichert-Ana, Lauro; de Araujo, Draulio B.; Riba, Jordi et al. (2015). “Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report”. Revista Brasileira de Psiquiatria 37 (1): 13–20. doi:10.1590/1516-4446-2014-1496. PMID 25806551.
Zeifman RJ, Singhal N, Dos Santos RG, Sanches RF, de Lima Osório F, Hallak JEC, Weissman CR (2021-2). “Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial”. Psychopharmacology (Berl) 238 (2): 453–459. doi:10.1007/s00213-020-05692-9. PMID 33118052.
Sampedro, Frederic; de la Fuente Revenga, Mario; Valle, Marta; et al. (2017). “Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities”. International Journal of Neuropsychopharmacology 20 (9): 698–711. doi:10.1093/ijnp/pyx036. PMC 5581489. PMID 28525587.
dos Santos, Rafael G; Balthazar, Fermanda M; Bouso, José C; et al. (2016). “The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging”. Journal of Psychopharmacology 30 (12): 1230–1247. doi:10.1177/0269881116652578. PMID 27287824.
Kuypers, K. P. C.; Riba, J.; de la Fuente Revenga, M.; et al. (2016). “Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking”. Psychopharmacology 233 (18): 3395–3403. doi:10.1007/s00213-016-4377-8. PMC 4989012. PMID 27435062.
Mazza, Marianna; Bouso, José Carlos; González, Débora; et al. (2012). “Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study”. PLoS ONE 7 (8): e42421. doi:10.1371/journal.pone.0042421. PMC 3414465. PMID 22905130.
Nutt, David J.; Rucker, James J.H.; Iliff, Jonathan; et al. (2017). “Psychiatry & the psychedelic drugs. Past, present & future”. Neuropharmacology. doi:10.1016/j.neuropharm.2017.12.040. PMID 29284138.
Halpern, John H (2004). “Hallucinogens and dissociative agents naturally growing in the United States” (pdf). Pharmacology & Therapeutics 102 (2): 131–138. doi:10.1016/j.pharmthera.2004.03.003. PMID 15163594.
Ott, Jonathan (1999). “Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine”. Journal of Psychoactive Drugs 31 (2): 171–177. doi:10.1080/02791072.1999.10471741. PMID 10438001.

erowid.org

Erowid. Erowid Ayahuasca Vault : Timeline, Erowid.org, 1996.
Saklad, Stephen R. Erowid MAOI Vault : Foods to Avoid, Micromedex Inc, 1994.
International control of the preparation "ayahuasca", letter from the United Nations International Narcotics Control Board

forbesjapan.com

Erin Blakemore; 訳・牧野建志 (2019年5月14日). “米国で注目の「伝統的幻覚剤」、最古の証拠発見か”. ナショナルジオグラフィック日本版. 2021年2月4日閲覧。同様の記事: Kristina Killgrove; 上田裕資 (2019年5月18日). “南米ボリビアで発見された1000年前のコカインや幻覚ドラッグ”. （フォーブスジャパン. 2021年2月5日閲覧。

kahpi.net

Xavier Francuski (2018年2月3日). “How To Prepare For Your First Ayahuasca Experience”. Kahpi. 2018年2月1日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

dos Santos, Rafael G.; Bouso, José Carlos; Hallak, Jaime E. C.; et al. (2017). “Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies”. Therapeutic Advances in Psychopharmacology 7 (4): 141–157. doi:10.1177/2045125316689030. PMC 5433617. PMID 28540034.
Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H.; et al. (2016). “Clinical applications of hallucinogens: A review.”. Experimental and Clinical Psychopharmacology 24 (4): 229–268. doi:10.1037/pha0000084. PMC 5001686. PMID 27454674.
Palhano-Fontes F, Barreto D, Onias H, et al. (2019-3). “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial”. Psychol Med 49 (4): 655–663. doi:10.1017/S0033291718001356. PMC 6378413. PMID 29903051.
Riba, J. (2003). “Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics”. Journal of Pharmacology and Experimental Therapeutics 306 (1): 73–83. doi:10.1124/jpet.103.049882. PMID 12660312.
Morales-García, Jose A.; de la Fuente Revenga, Mario; Alonso-Gil, Sandra; et al. (2017). “The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro”. Scientific Reports 7 (1): 5309. doi:10.1038/s41598-017-05407-9. PMC 5509699. PMID 28706205.
Osório, Flávia de L.; Sanches, Rafael F.; Macedo, Ligia R.; dos Santos, Rafael G.; Maia-de-Oliveira, João P.; Wichert-Ana, Lauro; de Araujo, Draulio B.; Riba, Jordi et al. (2015). “Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report”. Revista Brasileira de Psiquiatria 37 (1): 13–20. doi:10.1590/1516-4446-2014-1496. PMID 25806551.
Zeifman RJ, Singhal N, Dos Santos RG, Sanches RF, de Lima Osório F, Hallak JEC, Weissman CR (2021-2). “Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial”. Psychopharmacology (Berl) 238 (2): 453–459. doi:10.1007/s00213-020-05692-9. PMID 33118052.
Sampedro, Frederic; de la Fuente Revenga, Mario; Valle, Marta; et al. (2017). “Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities”. International Journal of Neuropsychopharmacology 20 (9): 698–711. doi:10.1093/ijnp/pyx036. PMC 5581489. PMID 28525587.
dos Santos, Rafael G; Balthazar, Fermanda M; Bouso, José C; et al. (2016). “The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging”. Journal of Psychopharmacology 30 (12): 1230–1247. doi:10.1177/0269881116652578. PMID 27287824.
Kuypers, K. P. C.; Riba, J.; de la Fuente Revenga, M.; et al. (2016). “Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking”. Psychopharmacology 233 (18): 3395–3403. doi:10.1007/s00213-016-4377-8. PMC 4989012. PMID 27435062.
Mazza, Marianna; Bouso, José Carlos; González, Débora; et al. (2012). “Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study”. PLoS ONE 7 (8): e42421. doi:10.1371/journal.pone.0042421. PMC 3414465. PMID 22905130.
Nutt, David J.; Rucker, James J.H.; Iliff, Jonathan; et al. (2017). “Psychiatry & the psychedelic drugs. Past, present & future”. Neuropharmacology. doi:10.1016/j.neuropharm.2017.12.040. PMID 29284138.
Halpern, John H (2004). “Hallucinogens and dissociative agents naturally growing in the United States” (pdf). Pharmacology & Therapeutics 102 (2): 131–138. doi:10.1016/j.pharmthera.2004.03.003. PMID 15163594.
Ott, Jonathan (1999). “Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine”. Journal of Psychoactive Drugs 31 (2): 171–177. doi:10.1080/02791072.1999.10471741. PMID 10438001.

ncbi.nlm.nih.gov

dos Santos, Rafael G.; Bouso, José Carlos; Hallak, Jaime E. C.; et al. (2017). “Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies”. Therapeutic Advances in Psychopharmacology 7 (4): 141–157. doi:10.1177/2045125316689030. PMC 5433617. PMID 28540034.
Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H.; et al. (2016). “Clinical applications of hallucinogens: A review.”. Experimental and Clinical Psychopharmacology 24 (4): 229–268. doi:10.1037/pha0000084. PMC 5001686. PMID 27454674.
Palhano-Fontes F, Barreto D, Onias H, et al. (2019-3). “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial”. Psychol Med 49 (4): 655–663. doi:10.1017/S0033291718001356. PMC 6378413. PMID 29903051.
Morales-García, Jose A.; de la Fuente Revenga, Mario; Alonso-Gil, Sandra; et al. (2017). “The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro”. Scientific Reports 7 (1): 5309. doi:10.1038/s41598-017-05407-9. PMC 5509699. PMID 28706205.
Sampedro, Frederic; de la Fuente Revenga, Mario; Valle, Marta; et al. (2017). “Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities”. International Journal of Neuropsychopharmacology 20 (9): 698–711. doi:10.1093/ijnp/pyx036. PMC 5581489. PMID 28525587.
Kuypers, K. P. C.; Riba, J.; de la Fuente Revenga, M.; et al. (2016). “Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking”. Psychopharmacology 233 (18): 3395–3403. doi:10.1007/s00213-016-4377-8. PMC 4989012. PMID 27435062.
Mazza, Marianna; Bouso, José Carlos; González, Débora; et al. (2012). “Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study”. PLoS ONE 7 (8): e42421. doi:10.1371/journal.pone.0042421. PMC 3414465. PMID 22905130.

nii.ac.jp

ci.nii.ac.jp

山本誠「シャーマニズムを依存症治療に接合する- ペルーアマゾンの「歌う家」、薬物依存リハビリセンター「タキワシ」訪問記」『四天王寺大学紀要』第62号、2016年、287-316頁、NAID 110010059957。
石川勇一「アマゾン・ネオ・シャーマニズムの心理過程の現象学的・仏教的研究」『トランスパーソナル心理学/精神医学』第15巻第1号、2016年2月、62-86頁、NAID 40020957856。

nikkeibp.co.jp

natgeo.nikkeibp.co.jp

Erin Blakemore; 訳・牧野建志 (2019年5月14日). “米国で注目の「伝統的幻覚剤」、最古の証拠発見か”. ナショナルジオグラフィック日本版. 2021年2月4日閲覧。同様の記事: Kristina Killgrove; 上田裕資 (2019年5月18日). “南米ボリビアで発見された1000年前のコカインや幻覚ドラッグ”. （フォーブスジャパン. 2021年2月5日閲覧。

ouramazingworld.org

Halpern, John H (2004). “Hallucinogens and dissociative agents naturally growing in the United States” (pdf). Pharmacology & Therapeutics 102 (2): 131–138. doi:10.1016/j.pharmthera.2004.03.003. PMID 15163594.

plos.org

Mazza, Marianna; Bouso, José Carlos; González, Débora; et al. (2012). “Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study”. PLoS ONE 7 (8): e42421. doi:10.1371/journal.pone.0042421. PMC 3414465. PMID 22905130.

sagami-wu.ac.jp

石川勇一「アマゾン・ネオ・シャーマニズムの心理過程の現象学的・仏教的研究」『トランスパーソナル心理学/精神医学』第15巻第1号、2016年2月、62-86頁、NAID 40020957856。

scielo.br

Osório, Flávia de L.; Sanches, Rafael F.; Macedo, Ligia R.; dos Santos, Rafael G.; Maia-de-Oliveira, João P.; Wichert-Ana, Lauro; de Araujo, Draulio B.; Riba, Jordi et al. (2015). “Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report”. Revista Brasileira de Psiquiatria 37 (1): 13–20. doi:10.1590/1516-4446-2014-1496. PMID 25806551.

sciencedirect.com

Nutt, David J.; Rucker, James J.H.; Iliff, Jonathan; et al. (2017). “Psychiatry & the psychedelic drugs. Past, present & future”. Neuropharmacology. doi:10.1016/j.neuropharm.2017.12.040. PMID 29284138.

shitennoji.ac.jp

山本誠「シャーマニズムを依存症治療に接合する- ペルーアマゾンの「歌う家」、薬物依存リハビリセンター「タキワシ」訪問記」『四天王寺大学紀要』第62号、2016年、287-316頁、NAID 110010059957。